Literature DB >> 21547579

VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.

Michelle J Nyhan1, Shereen M El Mashad, Tracey R O'Donovan, Sarfraz Ahmad, Chris Collins, Paul Sweeney, Eamonn Rogers, Gerald C O'Sullivan, Sharon L McKenna.   

Abstract

BACKGROUND: Von Hippel-Lindau (VHL) tumour suppressor gene inactivation is associated with clear cell renal cell carcinoma (CCRCC) development. The VHL protein (pVHL) has been proposed to regulate the expression of several proteins including Hypoxia Inducible Factor-α (HIF-α), carbonic anhydrase (CA)IX, heterogeneous nuclear ribonucleoprotein (hnRNP)A2/B1 and osteopontin. pVHL has been characterized in vitro, however, clinical studies are limited. We evaluated the impact of VHL genetic alterations on the expression of several pVHL protein targets in paired normal and tumor tissue.
METHODS: The VHL gene was sequenced in 23 CCRCC patients and VHL transcript levels were evaluated by Real-Time RT-PCR. Expression of pVHL's protein targets were determined by Western blotting in 17 paired patient samples.
RESULTS: VHL genetic alterations were identified in 43.5% (10/23) of CCRCCs. HIF-1α, HIF-2α and CAIX were up-regulated in 88.2% (15/17), 100% (17/17) and 88.2% (15/17) of tumors respectively and their expression is independent of VHL status. hnRNP A2/B1 and osteopontin expression was variable in CCRCCs and had no association with VHL genetic status.
CONCLUSION: As expression of these proposed pVHL targets can be achieved independently of VHL mutation (and possibly by hypoxia alone), this data suggests that other pVHL targets may be more crucial in renal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547579     DOI: 10.1007/s13402-011-0029-5

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  33 in total

1.  Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.

Authors:  M S Wiesener; P M Münchenhagen; I Berger; N V Morgan; J Roigas; A Schwiertz; J S Jürgensen; G Gruber; P H Maxwell; S A Löning; U Frei; E R Maher; H J Gröne; K U Eckardt
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

2.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

Authors:  C C Wykoff; N J Beasley; P H Watson; K J Turner; J Pastorek; A Sibtain; G D Wilson; H Turley; K L Talks; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

3.  Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma.

Authors:  Koviljka Matusan; Gordana Dordevic; Darko Stipic; Vladimir Mozetic; Ksenija Lucin
Journal:  J Surg Oncol       Date:  2006-09-15       Impact factor: 3.454

4.  Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.

Authors:  Jung Han Kim; Chul Won Jung; Yeon Hee Cho; Jeeyun Lee; Se-Hoon Lee; Ho Young Kim; Jinny Park; Joon-Oh Park; Kihyun Kim; Won Seog Kim; Young Suk Park; Young-Hyuck Im; Won Ki Kang; Keunchil Park
Journal:  Oncol Rep       Date:  2005-05       Impact factor: 3.906

5.  The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.

Authors:  P A Pioli; W F Rigby
Journal:  J Biol Chem       Date:  2001-08-21       Impact factor: 5.157

6.  HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.

Authors:  Stefano J Mandriota; Kevin J Turner; David R Davies; Paul G Murray; Neil V Morgan; Heidi M Sowter; Charles C Wykoff; Eamonn R Maher; Adrian L Harris; Peter J Ratcliffe; Patrick H Maxwell
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

7.  Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.

Authors:  Xi Na; Guan Wu; Charlotte K Ryan; Susan R Schoen; P Anthony di'Santagnese; Edward M Messing
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

8.  Downregulation of hnRNP A2/B1 expression in tumor cells under prolonged hypoxia.

Authors:  Mercedes Garayoa; Yan-Gao Man; Alfredo Martínez; Frank Cuttitta; James L Mulshine
Journal:  Am J Respir Cell Mol Biol       Date:  2003-01       Impact factor: 6.914

Review 9.  The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

10.  Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.

Authors:  Jean-Jacques Patard; Patricia Fergelot; Pierre I Karakiewicz; Tobias Klatte; Quoc-Dien Trinh; Nathalie Rioux-Leclercq; Jonathan W Said; Arie S Belldegrun; Allan J Pantuck
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

View more
  3 in total

Review 1.  The role of HIF1α in renal cell carcinoma tumorigenesis.

Authors:  Lorraine J Gudas; Leiping Fu; Denise R Minton; Nigel P Mongan; David M Nanus
Journal:  J Mol Med (Berl)       Date:  2014-06-12       Impact factor: 4.599

2.  PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.

Authors:  Baris Turkbey; Maria L Lindenberg; Stephen Adler; Karen A Kurdziel; Yolanda L McKinney; Juanita Weaver; Cathy D Vocke; Miriam Anver; Gennady Bratslavsky; Philip Eclarinal; Gideon Kwarteng; Frank I Lin; Nana Yaqub-Ogun; Maria J Merino; W Marston Linehan; Peter L Choyke; Adam R Metwalli
Journal:  Abdom Radiol (NY)       Date:  2016-01

3.  Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Juana Dornbusch; Aristeidis Zacharis; Matthias Meinhardt; Kati Erdmann; Ingmar Wolff; Michael Froehner; Manfred P Wirth; Stefan Zastrow; Susanne Fuessel
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.